Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024050 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00024050: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00024050 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00024050, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by peripheral stem cell transplantation in treating patients who have myelodysplastic syndrome.
Interventions
- DRUG cyclophosphamide
- DRUG methotrexate
- DRUG busulfan
- PROCEDURE allogeneic bone marrow transplantation
- DRUG cyclosporine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-02 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
What the finished NCT00024050 record still lists
NCT00024050 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00024050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00024050 about?
NCT00024050 is a clinical study titled "Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. PURPOSE: Phase II trial to study the effectiveness of chemotherapy f...
What is the current status of trial NCT00024050?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-02. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00024050?
The interventions under investigation include: cyclophosphamide (DRUG), methotrexate (DRUG), busulfan (DRUG), allogeneic bone marrow transplantation (PROCEDURE), cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00024050?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia